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EDITORIAL
Prospects for gene transfer into renal cells
In the current issue of Kidney International, Tsujie linked to insertional mutagenesis and have the potential
et al describe the use of gene transfer technology to for carcinogenesis, as well as reproductive toxicity.
selectively target renal interstitial fibroblasts [1]. This The work of Tsujie et al makes an important observation
work spotlights both the promise and the hurdles that in the field of experimental nephrology by demonstrating
attend this methodology. Gene transfer has the potential a novel approach to gene transfer. The authors show
to be one of the most important experimental tools to that retrograde administration of DNA through the urinary
broaden our understanding of disease processes as well tract reaches renal interstitial cells. Fluoroscein isothio-
as revolutionizing the approach of treating clinical disor- cyanate (FITC)-labeled oligodexoynucleotides (ODN) or
ders [2]. Gene transfer encompasses concepts that are truncated Epstein-Barr virus nuclear antigen 1 (pBNAct-
fundamental to life processes and thus profoundly im- N1acF) expression vector were combined with an artifi-
pacts the understanding and practice of medicine. How- cial viral envelope-type hemagglutinating virus of Japan
ever, the extraordinary potential, which had gained mo- liposome. The preparations were instilled into the rat
mentum in the last decade, has been tempered by kidney by retrograde infusion through the left ureter,
recognition of some technical limitations and early clini- incubated for 10 minutes while simultaneously clamping
cal disappointments. the renal vein. The tip of the catheter remained in the
Theoretically, the ability to manipulate, either by inac- ureter and did not ascend into the pelvis, which became
tivating or amplifying, the product of the 150,000 individ- distended by the procedure but sustained only mildly
ual genes that comprise the human genome should pro- elevated pressures. Immunofluorescence staining with
vide a very accurate blueprint for the basic organization rhodamine-labelled anti-type IV collagen antibodies re-
and function of cells, tissues, organs, and entire organ- vealed FITC-positive nuclei beyond the tubular base-
isms. By extension, disturbance in the gene product, such ment membrane but not in tubular epithelial cells, glo-
as a lack of a functional form, or expression of one or merular cells or macrophages. Transfected ODN were
more aberrant proteins, such as an oncogene or patho- observed in nuclei of interstitial fibroblasts, identified by
genic protein, underlie many diseases. Thus, manipula- counter staining with an anti-fibroblast antibody, ER-
tion of cellular function at its genetic root offers truly TR7. The gene transfer was observed in kidneys har-
limitless possibilities, and presents obvious advantages vested 10 minutes after transfection. Persistent expres-
to the relatively nonspecific inhibitors and agonists that sion was documented in interstitial cells 14 days after
are currently available through the traditional pharma- transfection while glomeruli, tubule cells, macrophages
cologic approach. However, the methodology to replace
and vasculature showed no expression of the transgene.
or inhibit specific genes at appropriate sites in a precise,
Clearly, the ureteral approach offers a more ready ac-
efficient, and safe manner remains elusive. Manipulation
cess to the kidney that had previously been approachedof genes involves several steps. Genes must reach and
only via the renal vasculature. The authors serendipi-gain entrance into the target cell; the gene must be ex-
tously found that retrograde transfection bypasses thepressed at sufficient levels and for a sufficient duration
tubule epithelial cells and appears to preferentially targetto modify cell functions. Since large DNA fragments
interstitial cells, but not other intrarenal cells such ascannot permeate the cell membrane, gene carriers, that
macrophages, endothelial cells or other vascular/glomer-is, vectors including attenuated or modified version of
ular cells. This notable observation requires further in-viruses or synthetic liposomes, must transport the DNA
vestigation. Cells may become transfected, but the mag-into cells. However, delivery of a sufficient amount of
nitude is insufficient to activate the marker gene and thusthe gene to the appropriate cells within a specific location
escape visual detection. Rigorous scrutiny to identify thehas been problematic [3]. In addition, the vectors per se
transfected cells and ascertain absence of transfected(as opposed to the transgene product) can induce an
gene in nonfibroblasts is warranted. Cell- and tissue-immunologic response in the host. Vectors have been
specificity studies are a very crucial area of ongoing in-
vestigation that has yielded several possibilities, includ-
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for certain breast cancer [5], a-fetoprotein for hepatomaÓ 2000 by the International Society of Nephrology
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studies were not specifically designed to target a specific
cell type, exploration of the mechanisms for the selectiv- REFERENCES
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